Shots: The approval was based on the P-III IMbrave150 study (n=501) assessing the combination of Tecentriq (1200 mg, IV) and Avastin (15 mg/kg, IV) or sorafenib (400 mg, bid) in […]readmore
Tags : Unresectable Hepatocellular Carcinoma
Shots: The approval is based on P-lll IMbrave150 study assessing Tecentriq (1200mg) and Avastin (100 mg/4 mL and 400 mg/16 mL) vs sorafenib in 501 patients in a ratio (2:1) […]readmore
Shots: The sBLA is based on P-III IMbrave150 study involve assessing of Tecentriq (1200mg, IV) + Avastin (IV, 15 mg/kg) vs Sorafenib (PO, 400mg, bid) in 501 patients in a […]readmore
Shots: The P-III IMbrave150 study involve assessing of Tecentriq (1200mg, IV) + Avastin (IV, 15 mg/kg) vs Sorafenib (PO, 400mg, bid) in 501 patients in a ratio 2:1 with unresectable […]readmore
Shots: The P-III IMbrave150 study involve assessing of Tecentriq (1200 mg on day 1 of each 21-day cycle) in combination with Avastin (15 mg/kg on day 1 of each 21-day […]readmore